Vir Biotechnology

Vir Biotechnology

VIR· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -17.8% in FY2025

Marianne De Backer, M.Sc., Ph.D., MBA is the CEO of Vir Biotechnology and was paid $7.8M in FY2025 (Dec), down 15%.

Pay$100 in the stock at the end of FY22 → $24
CEO pay is from each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Marianne De Backer, M.Sc., Ph.D., MBAFY2025
  2. 2Mark Eisner, M.D., M.P.H.FY2025
  3. 3Jason O’Byrne, MBAFY2025
  4. 4Vanina de Verneuil, J.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Vir Biotechnology paid its 4 named executives $13.8M in total in FY2025 (Dec). CEO Marianne De Backer, M.Sc., Ph.D., MBA was paid $7.8M of that.

Name
Marianne De Backer, M.Sc., Ph.D., MBAPresident, Chief Executive Officer and Director
Mark Eisner, M.D., M.P.H.Executive Vice President and Chief Medical OfficerNot disclosed
Jason O’Byrne, MBAExecutive Vice President and Chief Financial OfficerNot disclosed
Vanina de Verneuil, J.D.Executive Vice President, General Counsel and Corporate SecretaryNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers17

See all

The FY2025 (Dec) proxy of Vir Biotechnology names 17 peer companies for pay. Among Vir Biotechnology and these peers, CEO pay was 3rd highest of 7 and total shareholder return was 2nd highest of 7.

3rd highest of 7in Vir Biotechnology and its pay peers, FY2025 (Dec) by CEO pay:

$4.6M$11.4M

2nd highest of 7in Vir Biotechnology and its pay peers, FY2025 (Dec) by total shareholder return:

$6$34

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Jeffrey S. HatfieldDirector · 5 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
  • Norbert BischofbergerDirector · 1 yr on the boardIndependentCompensation, Science and Technology—Paid as an executive
  • Ramy FaridDirector · 1 yr on the boardIndependentAudit, Science and Technology—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Vir Biotechnology CEO pay fell 15% to $7.8M. The stock fell 18% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Vir Biotechnology Division head pay fell 14% to $2.4M. The stock fell 18% in FY2025 (Dec).
    DEF 14A
  3. Board
    Ramy Farid joined the board of Vir Biotechnology. Ramy Farid now sits on 2 public boards.
    3
  4. Pay
    Vir Biotechnology Former CFO pay fell 64% to $1.7M. The stock fell 27% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Vir Biotechnology CEO pay fell 77% to $9.3M. The stock fell 27% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Vir Biotechnology CTO pay fell 55% to $1.4M. The stock fell 27% in FY2024 (Dec).
    DEF 14A
  7. Board
    Norbert Bischofberger joined the board of Vir Biotechnology. Norbert Bischofberger now sits on 2 public boards.
    3
  8. Pay
    Vir Biotechnology Former Executive Vice President and Chief Administrative Officer pay rose 45% to $3.3M. The stock fell 60% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Vir Biotechnology Former Executive Vice President and Chief Administrative Officer pay fell 47% to $2.2M. The stock fell 40% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Vir Biotechnology Division head pay fell 32% to $4.4M. The stock fell 40% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Vir Biotechnology President pay fell 95% to $338.2K. The stock fell 60% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Vir Biotechnology Division head pay fell 13% to $4.4M. The stock fell 60% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Vir Biotechnology Former CFO pay fell 79% to $601.3K. The stock fell 60% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Vir Biotechnology Former CFO pay fell 44% to $2.9M. The stock fell 40% in FY2022 (Dec).
    DEF 14A
  15. Pay
    Vir Biotechnology CTO pay fell 13% to $3.1M. The stock fell 60% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Vir Biotechnology CTO pay fell 25% to $3.6M. The stock fell 40% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 16, 2026FY2025
Annual report10-KFeb 23, 2026FY2025
Proxy statementDEF 14AApr 17, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 19, 2024FY2023
Annual report10-KFeb 26, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data